Renal Denervation in High-Risk Patients With Hypertension
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Renal denervation (RDN) is under investigation for treatment of uncontrolled hypertension and might represent an attractive treatment for patients with high cardiovascular (CV) risk. It is important to determine whether baseline CV risk affects the efficacy of RDN. OBJECTIVES: The purpose of this study was to assess blood pressure (BP) reduction and event rates after RDN in patients with various comorbidities, testing the hypothesis that RDN is effective and durable in these high-risk populations. METHODS: BP reduction and adverse events over 3 years were evaluated for several high-risk subgroups in the GSR (Global proSpective registrY for syMPathetic renaL denervatIon in seleCted IndicatIons Through 3 Years Registry), an international registry of RDN in patients with uncontrolled hypertension (n = 2,652). Comparisons were made for patients age ≥65 years versus age <65 years, with versus without isolated systolic hypertension, with versus without atrial fibrillation, and with versus without diabetes mellitus. Baseline cardiovascular risk was estimated using the American Heart Association (AHA)/American College of Cardiology (ACC) atherosclerosis cardiovascular disease (ASCVD) risk score. RESULTS: Reduction in 24-h systolic BP at 3 years was -8.9 ± 20.1 mm Hg for the overall cohort, and for high-risk subgroups, BP reduction was -10.4 ± 21.0 mm Hg for resistant hypertension, -8.7 ± 17.4 mm Hg in patients age ≥65 years, -10.2 ± 17.9 mm Hg in patients with diabetes, -8.6 ± 18.7 mm Hg in isolated systolic hypertension, -10.1 ± 20.3 mm Hg in chronic kidney disease, and -10.0 ± 19.1 mm Hg in atrial fibrillation (p < 0.0001 compared with baseline for all). BP reduction in patients with measurements at 6, 12, 24, and 36 months showed similar reductions in office and 24-h BP for patients with varying baseline ASCVD risk scores, which was sustained to 3 years. Adverse event rates at 3 years were higher for patients with higher baseline CV risk. CONCLUSIONS: BP reduction after RDN was similar for patients with varying high-risk comorbidities and across the range of ASCVD risk scores. The impact of baseline risk on clinical event reduction by RDN-induced BP changes could be evaluated in further studies. (Global proSpective registrY for syMPathetic renaL denervatIon in seleCted IndicatIons Through 3 Years Registry; NCT01534299).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755
Azizi, M., Schmieder, R. E., Mahfoud, F., Weber, M. A., Daemen, J., Davies, J., Basile, J., Kirtane, A. J., Wang, Y., Lobo, M. D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31082-1 · Cited by 740
Self-citationSteinberg, J. S., Shabanov, V., Ponomarev, D., Losik, D., Ivanickiy, E., Kropotkin, E., Polyakov, K., Ptaszynski, P., Keweloh, B., Yao, C. J., et al. (2020) · JAMA · doi:10.1001/jama.2019.21187 · Cited by 243
Singh, R. R., McArdle, Z. M., Iudica, M., Easton, L. K., Booth, L. C., May, C. N., Parkington, H. C., Lombardo, P., Head, G. A., Lambert, G., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12250 · Cited by 86
Self-citation
Cited by
Mahfoud, F., Kandzari, D. E., Kario, K., Townsend, R. R., Weber, M. A., Schmieder, R. E., Tsioufis, K., Pocock, S., Dimitriadis, K., Choi, J. W., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00455-x · Cited by 295
Self-citationBarbato, E., Azizi, M., Schmieder, R. E., Lauder, L., Böhm, M., Brouwers, S., Bruno, R. M., Dudek, D., Kahan, T., Kandzari, D. E., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad054 · Cited by 188
Self-citationSafety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications
Kandzari, D. E., Townsend, R. R., Kario, K., Mahfoud, F., Weber, M. A., Schmieder, R. E., Pocock, S., Tsioufis, K., Konstantinidis, D., Choi, J., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.045 · Cited by 124
Self-citation(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation
Mahfoud, F., Townsend, R. R., Kandzari, D. E., Kario, K., Schmieder, R. E., Tsioufis, K., Pocock, S., David, S., Patel, K., Rao, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.044 · Cited by 115
Self-citation
Metadata
- Authors
- Mahfoud, F., Mancia, G., Schmieder, R., Narkiewicz, K., Ruilope, L., Schlaich, M., Whitbourn, R., Zirlik, A., Zeller, T., Stawowy, P., Cohen, S. A., Fahy, M., & Böhm, M.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 75
- Issue
- 23
- Pages
- 2879-2888
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3034082335
- Cited by
- 121
- References
- 7
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal Denervation in High-Risk Patients With Hypertension. https://app.cochat.ai/papers/10.1016/j.jacc.2020.04.036
- The paper
- Mahfoud, F., Mancia, G., Schmieder, R., Narkiewicz, K., Ruilope, L., Schlaich, M., Whitbourn, R., Zirlik, A., Zeller, T., Stawowy, P., Cohen, S. A., Fahy, M., & Böhm, M. (2020). Renal Denervation in High-Risk Patients With Hypertension. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2020.04.036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.